(SNY) Sanofi - Ratings and Ratios
Vaccines, Oncology, Immunology, Neurology, Rare Diseases
SNY EPS (Earnings per Share)
SNY Revenue
Description: SNY Sanofi
Sanofi is a global healthcare company that develops, manufactures, and markets a diverse portfolio of therapeutic solutions, including medicines and vaccines, across various therapeutic areas such as immunology, rare diseases, neurology, and oncology. The companys broad product range includes pediatric vaccines, influenza vaccines, and booster shots, as well as treatments for various diseases. Sanofis product pipeline is further enhanced by its multiple collaborations and license agreements with other biotech and pharmaceutical companies.
From a strategic perspective, Sanofis partnerships with companies like Exscientia, ABL Bio, and Innate Pharma indicate a focus on innovative treatments and technologies, including small-molecule oncology treatments and natural killer cell engagers. Additionally, collaborations with companies like IGM Biosciences and Kymera Therapeutics suggest a commitment to developing novel therapies for immune-inflammatory diseases. These partnerships have the potential to drive growth and expand Sanofis offerings in the market.
To evaluate Sanofis performance, key performance indicators (KPIs) such as revenue growth, R&D expenditure as a percentage of sales, and return on equity (RoE) can be considered. With a RoE of 8.48%, Sanofis profitability is relatively stable. The companys dividend yield and payout ratio can also provide insights into its ability to return value to shareholders. Furthermore, metrics like the number of new product launches and the success rate of its pipeline candidates can help assess Sanofis innovation capacity and future growth prospects.
From a valuation perspective, Sanofis price-to-earnings (P/E) ratio of 16.37 and forward P/E of 9.98 suggest that the stock may be undervalued relative to its expected earnings growth. The companys market capitalization of $118.48 billion indicates a significant presence in the global pharmaceuticals market. To further assess the stocks attractiveness, metrics like the EV/EBITDA ratio and the stocks beta can be analyzed to understand its risk profile and relative valuation.
SNY Stock Overview
| Market Cap in USD | 123,241m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 2002-07-01 |
SNY Stock Ratings
| Growth Rating | 11.4% |
| Fundamental | 57.0% |
| Dividend Rating | 58.1% |
| Return 12m vs S&P 500 | -21.0% |
| Analyst Rating | 4.18 of 5 |
SNY Dividends
| Dividend Yield 12m | 4.41% |
| Yield on Cost 5y | 5.34% |
| Annual Growth 5y | 3.05% |
| Payout Consistency | 97.2% |
| Payout Ratio | 45.9% |
SNY Growth Ratios
| Growth Correlation 3m | 8.2% |
| Growth Correlation 12m | -25% |
| Growth Correlation 5y | 71.6% |
| CAGR 5y | 3.81% |
| CAGR/Max DD 5y | 0.11 |
| Sharpe Ratio 12m | -0.52 |
| Alpha | -14.70 |
| Beta | 0.242 |
| Volatility | 22.03% |
| Current Volume | 2004.7k |
| Average Volume 20d | 2044.5k |
| Stop Loss | 48.4 (-3.1%) |
| Signal | 0.74 |
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income (9.13b TTM) > 0 and > 6% of Revenue (6% = 2.59b TTM) |
| FCFTA 0.02 (>2.0%) and ΔFCFTA -1.51pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 18.45% (prev 0.09%; Δ 18.36pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.03 (>3.0%) and CFO 3.56b <= Net Income 9.13b (YES >=105%, WARN >=100%) |
| Net Debt (6.93b) to EBITDA (9.47b) ratio: 0.73 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.27 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (2.47b) change vs 12m ago -1.36% (target <= -2.0% for YES) |
| Gross Margin 71.63% (prev 67.51%; Δ 4.12pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 33.86% (prev 44.76%; Δ -10.90pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 9.12 (EBITDA TTM 9.47b / Interest Expense TTM 877.8m) >= 6 (WARN >= 3) |
Altman Z'' 3.80
| (A) 0.06 = (Total Current Assets 37.02b - Total Current Liabilities 29.06b) / Total Assets 124.96b |
| (B) 0.52 = Retained Earnings (Balance) 65.09b / Total Assets 124.96b |
| (C) 0.06 = EBIT TTM 8.00b / Avg Total Assets 127.36b |
| (D) 1.20 = Book Value of Equity 65.54b / Total Liabilities 54.68b |
| Total Rating: 3.80 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 56.98
| 1. Piotroski 5.0pt = 0.0 |
| 2. FCF Yield 1.92% = 0.96 |
| 3. FCF Margin 4.95% = 1.24 |
| 4. Debt/Equity 0.30 = 2.46 |
| 5. Debt/Ebitda 2.19 = -0.38 |
| 6. ROIC - WACC 1.27% = 1.59 |
| 7. RoE 12.39% = 1.03 |
| 8. Rev. Trend -24.77% = -1.24 |
| 9. Rev. CAGR -7.08% = -1.18 |
| 10. EPS Trend 0.00% = 0.00 |
| 11. EPS CAGR 26.96% = 2.50 |
What is the price of SNY shares?
Over the past week, the price has changed by -1.32%, over one month by +0.93%, over three months by -3.94% and over the past year by -7.05%.
Is Sanofi a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of SNY is around 48.99 USD . This means that SNY is currently overvalued and has a potential downside of -1.9%.
Is SNY a buy, sell or hold?
- Strong Buy: 5
- Buy: 3
- Hold: 3
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the SNY price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 62.2 | 24.5% |
| Analysts Target Price | 64.1 | 28.4% |
| ValueRay Target Price | 53.3 | 6.8% |
Last update: 2025-08-21 11:35
SNY Fundamental Data Overview
CCE Cash And Equivalents = 15.36b EUR (Cash And Short Term Investments, last quarter)
P/E Trailing = 16.8433
P/E Forward = 11.2108
P/S = 2.6945
P/B = 1.5121
P/EG = 0.8694
Beta = 0.407
Revenue TTM = 43.13b EUR
EBIT TTM = 8.00b EUR
EBITDA TTM = 9.47b EUR
Long Term Debt = 13.20b EUR (from longTermDebt, last quarter)
Short Term Debt = 7.56b EUR (from shortTermDebt, last quarter)
Debt = 20.76b EUR (Calculated: Short Term 7.56b + Long Term 13.20b)
Net Debt = 6.93b EUR (from netDebt column, last quarter)
Enterprise Value = 111.19b EUR (105.79b + Debt 20.76b - CCE 15.36b)
Interest Coverage Ratio = 9.12 (Ebit TTM 8.00b / Interest Expense TTM 877.8m)
FCF Yield = 1.92% (FCF TTM 2.13b / Enterprise Value 111.19b)
FCF Margin = 4.95% (FCF TTM 2.13b / Revenue TTM 43.13b)
Net Margin = 21.16% (Net Income TTM 9.13b / Revenue TTM 43.13b)
Gross Margin = 71.63% ((Revenue TTM 43.13b - Cost of Revenue TTM 12.24b) / Revenue TTM)
Tobins Q-Ratio = 1.70 (Enterprise Value 111.19b / Book Value Of Equity 65.54b)
Interest Expense / Debt = 0.42% (Interest Expense 87.0m / Debt 20.76b)
Taxrate = 17.98% (from yearly Income Tax Expense: 1.20b / 6.70b)
NOPAT = 6.57b (EBIT 8.00b * (1 - 17.98%))
Current Ratio = 1.27 (Total Current Assets 37.02b / Total Current Liabilities 29.06b)
Debt / Equity = 0.30 (Debt 20.76b / last Quarter total Stockholder Equity 70.01b)
Debt / EBITDA = 2.19 (Net Debt 6.93b / EBITDA 9.47b)
Debt / FCF = 9.72 (Debt 20.76b / FCF TTM 2.13b)
Total Stockholder Equity = 73.65b (last 4 quarters mean)
RoA = 7.30% (Net Income 9.13b, Total Assets 124.96b )
RoE = 12.39% (Net Income TTM 9.13b / Total Stockholder Equity 73.65b)
RoCE = 9.22% (Ebit 8.00b / (Equity 73.65b + L.T.Debt 13.20b))
RoIC = 7.10% (NOPAT 6.57b / Invested Capital 92.41b)
WACC = 5.83% (E(105.79b)/V(126.55b) * Re(6.91%)) + (D(20.76b)/V(126.55b) * Rd(0.42%) * (1-Tc(0.18)))
Shares Correlation 5-Years: -97.50 | Cagr: -0.42%
Discount Rate = 6.91% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 70.46% ; FCFE base≈2.95b ; Y1≈1.94b ; Y5≈885.5m
Fair Price DCF = 7.14 (DCF Value 17.41b / Shares Outstanding 2.44b; 5y FCF grow -40.0% → 3.0% )
Revenue Correlation: -24.77 | Revenue CAGR: -7.08%
Rev Growth-of-Growth: -32.17
EPS Correlation: 0.00 | EPS CAGR: 26.96%
EPS Growth-of-Growth: 128.9
Additional Sources for SNY Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle